Ligand Pharmaceuticals Incorporated
LGND
$210.99
$3.191.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.67M | 115.46M | 47.63M | 45.33M | 42.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.67M | 115.46M | 47.63M | 45.33M | 42.81M |
| Cost of Revenue | 2.22M | 24.82M | 9.47M | 54.93M | 3.72M |
| Gross Profit | 57.45M | 90.64M | 38.15M | -9.60M | 39.09M |
| SG&A Expenses | 25.03M | 28.45M | 20.18M | 18.80M | 25.61M |
| Depreciation & Amortization | 8.10M | 8.10M | 8.26M | 8.26M | 8.26M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.63M | 61.36M | 37.91M | 81.99M | 41.13M |
| Operating Income | 20.04M | 54.10M | 9.72M | -36.66M | 1.69M |
| Income Before Tax | 56.78M | 141.14M | 11.22M | -50.18M | -39.20M |
| Income Tax Expenses | 12.00M | 23.86M | 6.38M | -7.73M | -8.11M |
| Earnings from Continuing Operations | 44.78M | 117.27M | 4.85M | -42.45M | -31.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.78M | 117.27M | 4.85M | -42.45M | -31.09M |
| EBIT | 20.04M | 54.10M | 9.72M | -36.66M | 1.69M |
| EBITDA | 28.25M | 63.26M | 17.82M | -28.35M | 10.31M |
| EPS Basic | 2.27 | 5.99 | 0.25 | -2.21 | -1.64 |
| Normalized Basic EPS | 3.70 | 1.83 | 0.33 | -1.23 | -1.51 |
| EPS Diluted | 2.12 | 5.68 | 0.24 | -2.21 | -1.64 |
| Normalized Diluted EPS | 3.45 | 1.74 | 0.32 | -1.23 | -1.51 |
| Average Basic Shares Outstanding | 19.73M | 19.58M | 19.33M | 19.19M | 18.97M |
| Average Diluted Shares Outstanding | 21.14M | 20.63M | 19.93M | 19.19M | 18.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |